The Trading Halt Is the Mechanism: How Percheron Therapeutics Funds Its Drug Development

When the Australian Securities Exchange halts trading in a small biotech like Percheron Therapeutics, the pause is usually described as protection. Investors are kept out so the company can make a "material announcement" without people trading on incomplete information. That is true enough. But if you follow the trail of what actually happens next — the announcement, the capital raise, the dilution — the halt stops looking like investor protection and starts looking like a mechanism. A way to freeze the price at the last known level while the company prepares to sell new shares at a discount to that same level.

Percheron has done this cycle more times than the company's name changes. (It used to be Antisense Therapeutics. Then it became Percheron Therapeutics. The plumbing stayed the same.) The company is an Australian-listed, clinical-stage biotech with a lead drug candidate called HMBD-002 — an antibody that targets a protein called VISTA, which cancer cells use to suppress the immune system. The science is legitimate. The business model is a different question.

The last halt before a capital raising came in October 2024. Before that, a halt in June 2025 preceded the announcement of a licensing deal with Hummingbird Bioscience for HMBD-002. And the cycle repeats because there is only one source of cash for a company that has never earned revenue from a product: selling more ownership.

Here is what happens inside one of these cycles.

Percheron's most recent capital raise is the cleanest example. In March 2026, the company launched what is called a "non-renounceable entitlement offer" — which is the Australian market's way of saying existing shareholders can buy new shares at a discount, but they cannot sell their entitlement to someone else. The offer was structured as two new shares for every five held, priced at 0.5 Australian cents each, with a free-attaching option exercisable at 1 cent for every two new shares purchased.

That option is the part worth paying attention to. It means the company is not just issuing new shares — it is issuing call options on future shares, at a strike price that sits between the issue price and the pre-offer market price. The options don't expire for two years. When they do get exercised, there is another round of dilution baked into the deal.

The numbers tell the dilution story directly. Before the offer, Percheron had about 1.09 billion shares outstanding. After, it had roughly 1.52 billion. That is a 40% increase in shares from a single raise. On top of those shares, the company issued about 217 million new options, bringing the total options outstanding to more than 406 million. If all those options were exercised, the fully diluted share count would be significantly higher than 1.52 billion.

But the entitlement portion — the shares offered directly to existing shareholders — only raised about 800,000 Australian dollars. The rest of the target, about 1.4 million dollars, came from a "shortfall offer," which is what happens when shareholders decline their discounted purchase and someone else has to absorb the shares. New investors stepped in for the shortfall. The entire raise brought in approximately 2.2 million Australian dollars before costs.

At an issue price of half a cent per share, raising 2.2 million dollars requires issuing 440 million new shares. Those are not small numbers relative to a company trading in the fractions of a cent.

The cash math is what makes the cycle repeat.

Percheron ended the June 2026 quarter with just over 4 million Australian dollars in cash and term deposits, down from about 10.2 million at the same point in the prior year. The company's quarterly operating cash burn sits around 1 million dollars. That gives it roughly four quarters of runway — into the first quarter of 2027, according to analyst estimates.

The company is spending that money advancing HMBD-002 toward a Phase II clinical trial, which management expects to begin in the fourth quarter of 2026. The drug substance has already been manufactured by Hummingbird Bioscience under their licensing agreement, and Percheron is working through the fill-and-finish packaging stage. The Phase I trial showed the drug was safe at a 720-milligram once-weekly dose and showed pharmacological activity. Phase II is designed as an adaptive basket study — multiple cancer types tested at once, with only the most promising arms continuing.

But Phase II is where the money requirement jumps. Edison Investment Research, which follows the stock, estimates that additional capital or a partnering transaction will be needed to advance and complete the Phase II study. The 2.2 million dollars from the March raise was enough to get Percheron to the starting gate. Running the race costs more.

The licensing agreement with Hummingbird adds another layer to the picture. Hummingbird Bioscience granted Percheron exclusive worldwide rights to develop and commercialize HMBD-002, with Percheron owing up to 290 million US dollars in combined upfront and milestone payments, plus royalties on net sales. Most of that 290 million is locked behind development and commercial milestones — payments Percheron will owe only if the drug actually works and sells. That is how these licensing deals read: modest upfront cost, enormous contingent future liability. Percheron got a Phase II-ready asset without writing a massive check today, but if the drug progresses, the company will need either a big partner or a very long string of smaller capital raises to fund the milestones as they come due.

Here is the structural question an investor holds when they own a share of Percheron.

The stock trades around 0.5 Australian cents. Edison values the company at 84.4 million Australian dollars, which works out to 5.5 cents per share. That is an 11-fold gap between the market price and one analyst's valuation. The gap exists because the market is pricing in a low probability of success — the drug might fail in Phase II, the milestones might never trigger, the cash will run out, and another dilutive raise will follow. The analyst is pricing in the scenario where the drug works, VISTA becomes a validated target, and the milestones and royalties flow back.

Both readings are internally consistent. The actual investment is a bet on which scenario wins, with dilution as the structural tax along the way.

Percheron just announced a CEO change in August 2026, with Dr. Michael Baker — a former CEO of Arovella Therapeutics — taking over in October. The board's logic is that Phase II development needs someone who has shepherded a clinical program through trials before. That is a fair institutional move. But changing the driver does not change the fuel equation. The company still needs to fund a multi-arm Phase II trial with a cash balance of 4 million dollars and a burn rate of roughly 1 million per quarter.

The trading halt mechanism is what lets this whole structure function smoothly. Without it, the stock would drop on the announcement, and the discounted issue price would have to be discounted further. The halt gives the company a clean entry point. Existing shareholders who participate get the discount. Those who don't — which is most of them, given the tiny take-up on the entitlement portion — get diluted by new money coming in at that same discount. The new shareholders then face the same decision in the next cycle.

That is not a critique of the structure. It is how nano-cap biotech funding works. The company is too small for a bond market, too risky for a bank loan, and too early-stage for revenue-based financing. Equity is the only currency available. The question for investors is whether the potential upside from HMBD-002 — if the drug succeeds, the milestones alone represent hundreds of millions of dollars in value — justifies absorbing a pattern of dilution that has already grown the share count by 40% in a single raise, with more certainty coming before Phase II completes.

Percheron is a real company with a real drug candidate moving through a real trial pipeline. The HMBD-002 antibody targets a legitimate immunotherapy pathway, the Phase I data was encouraging, and the Phase II design is rational. But the business model is a funding treadmill, and every step on it costs existing shareholders a piece of the pie. The next step is already scheduled. The cash will not last into 2027. The raise — whether called an entitlement offer, a placement, or a share purchase plan — will come. The trading halt that precedes it will do its quiet work. And the share count will grow again.

Understanding that cycle doesn't make the investment wrong. It just makes the cost of the bet visible.